249 related articles for article (PubMed ID: 36485128)
1. Targeting inflammation in lower-risk MDS.
Gonzalez-Lugo JD; Verma A
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):382-387. PubMed ID: 36485128
[TBL] [Abstract][Full Text] [Related]
2. Novel combinations to improve hematopoiesis in myelodysplastic syndrome.
Syed K; Naguib S; Liu ZJ; Cimmino L; Yang FC
Stem Cell Res Ther; 2020 Mar; 11(1):132. PubMed ID: 32197634
[TBL] [Abstract][Full Text] [Related]
3. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
4. Next-generation therapy for lower-risk MDS.
Sébert M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):59-64. PubMed ID: 38066862
[TBL] [Abstract][Full Text] [Related]
5. Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells.
Wobus M; Mies A; Asokan N; Oelschlägel U; Möbus K; Winter S; Cross M; Weidner H; Rauner M; Hofbauer LC; Bornhäuser M; Platzbecker U
Leukemia; 2021 Oct; 35(10):2936-2947. PubMed ID: 34002031
[TBL] [Abstract][Full Text] [Related]
6. Management of patients with lower-risk myelodysplastic syndromes.
Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N
Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487
[TBL] [Abstract][Full Text] [Related]
7. [Senescent Mesenchymal Stem Cells Contribute to Progression of Myelodysplastic Syndromes-Review].
Pang YB; Li WW; Luo JM; Ji J; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):942-946. PubMed ID: 29950248
[TBL] [Abstract][Full Text] [Related]
8. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.
Zhou L; McMahon C; Bhagat T; Alencar C; Yu Y; Fazzari M; Sohal D; Heuck C; Gundabolu K; Ng C; Mo Y; Shen W; Wickrema A; Kong G; Friedman E; Sokol L; Mantzaris I; Pellagatti A; Boultwood J; Platanias LC; Steidl U; Yan L; Yingling JM; Lahn MM; List A; Bitzer M; Verma A
Cancer Res; 2011 Feb; 71(3):955-63. PubMed ID: 21189329
[TBL] [Abstract][Full Text] [Related]
9. Innate immune signaling in the myelodysplastic syndromes.
Starczynowski DT; Karsan A
Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
[TBL] [Abstract][Full Text] [Related]
11. Signal transduction inhibitors in treatment of myelodysplastic syndromes.
Bachegowda L; Gligich O; Mantzaris I; Schinke C; Wyville D; Carrillo T; Braunschweig I; Steidl U; Verma A
J Hematol Oncol; 2013 Jul; 6():50. PubMed ID: 23841999
[TBL] [Abstract][Full Text] [Related]
12. Targeting Immune Signaling Pathways in Clonal Hematopoiesis.
Azrakhsh NA; Mensah-Glanowska P; Sand K; Kittang AO
Curr Med Chem; 2019; 26(28):5262-5277. PubMed ID: 30907306
[TBL] [Abstract][Full Text] [Related]
13. Current and emerging strategies for management of myelodysplastic syndromes.
Saygin C; Carraway HE
Blood Rev; 2021 Jul; 48():100791. PubMed ID: 33423844
[TBL] [Abstract][Full Text] [Related]
14. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
Nakajima H
Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
[TBL] [Abstract][Full Text] [Related]
15. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment.
Marques FK; Sabino AP
Biomed Pharmacother; 2022 Dec; 156():113905. PubMed ID: 36306593
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.
Zhou L; Nguyen AN; Sohal D; Ying Ma J; Pahanish P; Gundabolu K; Hayman J; Chubak A; Mo Y; Bhagat TD; Das B; Kapoun AM; Navas TA; Parmar S; Kambhampati S; Pellagatti A; Braunchweig I; Zhang Y; Wickrema A; Medicherla S; Boultwood J; Platanias LC; Higgins LS; List AF; Bitzer M; Verma A
Blood; 2008 Oct; 112(8):3434-43. PubMed ID: 18474728
[TBL] [Abstract][Full Text] [Related]
18. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M
J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390
[TBL] [Abstract][Full Text] [Related]
19. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
Chan O; Komrokji RS
Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
[TBL] [Abstract][Full Text] [Related]
20. What constitutes meaningful improvement in myelodysplastic syndromes?
Chandhok NS; Sekeres MA
Leuk Lymphoma; 2022 Nov; 63(11):2528-2535. PubMed ID: 35699987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
